Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177319 | 0.91 | TYMS (0.42) | TYMSTK1 | |
| SCHEMBL2030339 | 0.89 | TK1 (0.38) | TYMSTK1 | |
| SCHEMBL7535867 | 0.88 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL9564565 | 0.88 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL60737 | 0.88 | TK1 (0.52) | TYMSTK1 | |
| SCHEMBL5486404 | 0.87 | LMNA (0.47) | TYMSTK1 | |
| SCHEMBL5086844 | 0.87 | TK1 (0.47) | TYMSTK1 | |
| SCHEMBL1501551 | 0.87 | TYMS (0.44) | TYMSTK1 | |
| SCHEMBL7602619 | 0.86 | TK1 (0.43) | TYMSTK1 | |
| SCHEMBL2027058 | 0.86 | LMNA (0.50) | TYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268978-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110144319-A1 | Modified Oligonucleotides and Applications Thereof | Life Technologies Corporation (US) | 2011-06-16 | — | — | US | disclosed |
| US-7807376-B2 | Modified oligonucleotides and applications thereof | Life Technologies Corporation (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100112712-A1 | Modified Oligonucleotides and Applications Thereof | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-7585649-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090148846-A1 | Modified Oligonucleotides and Applications Thereof | APPLIED BIOSYSTEMS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7414118-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144319-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | TYMS 57/4885L3MBTL1 1684/4885TK1 170/4885 |
| US-20100112712-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | TYMS 57/4885L3MBTL1 1684/4885TK1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.